Managing missed injections
Decision Tree for managing the injection schedule
There are a number of options available for patients who miss their injection visit. Below, you will find an interactive Decision Tree that allows you to see how a delayed or missed injection visit affects a patient’s overall VOCABRIA + REKAMBYS treatment schedule.
If a patient delays or misses a treatment appointment, it’s important to reassess whether long-acting treatment remains appropriate for them.1,2
If treatment is discontinued, it is essential to start alternative ARV therapy no later than two months after the final injections (or one month if after first initiation injections) in order to minimise the risk of resistance.1
Is the patient’s appointment on their Target Treatment Date?
Proceed with injections as scheduled and maintain original Target Treatment Date for future injection
Is the patient’s appointment within the Flexible Dosing Window (+/- 7 days)?
Proceed with injections as scheduled and maintain original Target Treatment Date for future injection
Did the patient plan to do oral bridging with cabotegravir and rilpivirine tablets?
Does the oral bridging period exceed 2 months?
Which injection visit has the patient missed?
THE DATE THAT INJECTIONS ARE GIVEN WILL BECOME THE PATIENT'S NEW TARGET TREATMENT DATE
An alternative oral regimen is recommended.
On the day that oral bridging is completed, proceed with injections based on guidance for which injection visit was delayed or missed.1,2
THE DATE THAT INJECTIONS ARE GIVEN WILL BECOME THE PATIENT'S NEW TARGET TREATMENT DATE
On the day that oral bridging is completed, proceed with injections based on guidance for which injection visit was delayed or missed.1,2
THE DATE THAT INJECTIONS ARE GIVEN WILL BECOME THE PATIENT'S NEW TARGET TREATMENT DATE
ARV=antiretroviral.
References:
- VOCABRIA Summary of Product Characteristics. ViiV Healthcare; 2020.
- REKAMBYS Summary of Product Characteristics. Janssen Healthcare; 2020.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
REKAMBYS (rilpivirine long acting injection), including the trademark is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.
PM-GB-CBR-WCNT-210001 I October 2021
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
